There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality and Efficiency in Health Care (IQWiG) gave its opinion that its wet age-related macular degeneration treatment Eylea (aflibercept) offers no added benefit over the current standard therapy.
Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any suitable data for this comparison, the IQWiG said following its assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG). The drug has been approved in Germany for this indication since November 2012.
The Federal Joint Committee (G-BA) specified the drug ranibizumab (Novartis’ Lucentis) as appropriate comparator therapy. In its dossier Bayer cited two approval studies of aflibercept that directly compared aflibercept with ranibizumab. But in these studies, ranibizumab was not used according to its approval status. For instance, the continuation or discontinuation of treatment was not made dependent on whether the patients had achieved stable visual acuity or not.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze